Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Tailor: Interventional Study Evaluating Physician's Choice of Ibrutinib Monotherapy or Ibrutinib-Venetoclax Combination Using Dose Modifications and Alternate Dosing Approaches in Patients with Untreated Chronic Lymphocytic Leukemia

Jeff P. Sharman, Jan A. Burger, Jacqueline Barrientos, Philip Kuruvilla, Sima Patel, Gabriel Krigsfeld, Sowmya Srikanthan, Bothayna Messahel, Wasiulla Khan, Emma Smith, Paolo Ghia

Blood (2023) 142 (Supplement 1): 6564.

https://doi.org/10.1182/blood-2023-174751

Published: 2023

Journal Articles

First-Line Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O): 55-Month Follow-up from the Glow Study

Blood (2023) 142 (Supplement 1): 634.

https://doi.org/10.1182/blood-2023-177713

Published: 2023

Journal Articles

Autophagy Is a Key Myeloma Survival Pathway That Can Be Manipulated Therapeutically to Enhance Apoptosis

Lauren I Aronson, Emma L Davenport, Serena G Giuntoli, Muralikrishnan Srikanth, Emma Smith, Gareth J Morgan, MD, PhD, Faith Davies

Blood (2010) 116 (21): 4083.

https://doi.org/10.1182/blood.V116.21.4083.4083

Published: 2010

Journal Articles

Inhibitors of Heat Shock Protein 72 Induction Enhance Apoptosis Induced by Hsp90 Inhibitors

Emma Davenport, PhD, Athanasia Zeisig, PhD, Lauren Wiseglass, Hannah E. Moore, Sarah L. Hockley, PhD, David Gonzalez, PhD, Emma Smith, PhD, Swee Sharp, PhD, Paul Workman, PhD, Gareth J Morgan, MD.PhD., Faith Davies, MD

Blood (2008) 112 (11): 2625.

https://doi.org/10.1182/blood.V112.11.2625.2625

Published: 2008

Journal Articles

Notch Activation Converts B Cells into a T Cell Fate at the Earliest Stages of B Cell Committed Progenitors.

Jalal Taneera, Emma Smith, Mikael Sigvardsson, Emil Hansson, Urban Lindahl, Inga-Lill Martensson, Sten Eirik Jacobsen

Blood (2005) 106 (11): 3151.

https://doi.org/10.1182/blood.V106.11.3151.3151

Published: 2005

NARROW

Tailor: Interventional Study Evaluating Physician's Choice of Ibrutinib Monotherapy or Ibrutinib-Venetoclax Combination Using Dose Modifications and Alternate Dosing Approaches in Patients with Untreated Chronic Lymphocytic Leukemia

First-Line Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O): 55-Month Follow-up from the Glow Study

Autophagy Is a Key Myeloma Survival Pathway That Can Be Manipulated Therapeutically to Enhance Apoptosis

Inhibitors of Heat Shock Protein 72 Induction Enhance Apoptosis Induced by Hsp90 Inhibitors

Notch Activation Converts B Cells into a T Cell Fate at the Earliest Stages of B Cell Committed Progenitors.

Email alerts

ASH Publications

American Society of Hematology

Tailor: Interventional Study Evaluating Physician's Choice of Ibrutinib Monotherapy or Ibrutinib-Venetoclax Combination Using Dose Modifications and Alternate Dosing Approaches in Patients with Untreated Chronic Lymphocytic Leukemia

First-Line Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O): 55-Month Follow-up from the Glow Study

Autophagy Is a Key Myeloma Survival Pathway That Can Be Manipulated Therapeutically to Enhance Apoptosis

Inhibitors of Heat Shock Protein 72 Induction Enhance Apoptosis Induced by Hsp90 Inhibitors

Notch Activation Converts B Cells into a T Cell Fate at the Earliest Stages of B Cell Committed Progenitors.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only